Intellia stock dips following safety event in Phase III gene therapy trial
This comes at a challenging time for gene therapies, as multiple serious AEs and fatalities have been recently reported.
30 May 2025
30 May 2025
This comes at a challenging time for gene therapies, as multiple serious AEs and fatalities have been recently reported.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.